CALCA and migraine disorder: The development of monoclonal antibodies against CGRP and its receptor for migraine prophylaxis and antagonists of the CGRP receptor (gepants) for the treatment of acute migraine attacks and their prevention was a breakthrough in migraine treatment (reviewed in [2]).